GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Siemens Healthineers AG (OTCPK:SMMNY) » Definitions » Quality Rank

SMMNY (Siemens Healthineers AG) Quality Rank


View and export this data going back to 2018. Start your Free Trial

What is Siemens Healthineers AG Quality Rank?

The Quality Rank measures the business quality of a company relative to other companies. It is ranked based on the strength of the balance sheet, as well as the profitability and growth of the business. The ranked companies are split in equal numbers and then ranked from 1 to 10, with 10 being the highest.

The rank of balance sheet (30%)

The rank of balance sheet is done through the ranking of:
  • Interest coverage
  • Zscore
  • Debt to revenue
  • Equity to asset
  • Cash to debt

The rank of Profitability (70%)

The ranking of Profitability is done by ranking:
  • Operating margin mean rank (10-year mean average profit margine)
  • Operating margin growth rank
  • Fscore
  • Predictability rank
  • Revenue growth rank (5 year), when the growth is higher than 25%, set it as 25%
  • Num of year profit (number of years that is profitable within the last 10 years)
  • ROIC median (10-year median of ROIC)

Siemens Healthineers AG Quality Rank Related Terms

Thank you for viewing the detailed overview of Siemens Healthineers AG's Quality Rank provided by GuruFocus.com. Please click on the following links to see related term pages.


Siemens Healthineers AG Business Description

Address
Siemensstrasse 3, Forchheim, BY, DEU, 91301
Siemens Healthineers is engaged in therapeutic imaging, radiotherapy, laboratory, and point-of-care diagnostics. The imaging segment (55% of sales in fiscal 2023) includes magnetic resonance imaging, computed tomography, X-ray systems, molecular imaging, and ultrasound. The Varian segment (16% of sales) offers radiotherapy and other oncology solutions. The portfolio of the diagnostics segment (21%) includes in vitro diagnostics products offered to providers and point-of-care diagnostics. The advanced therapies segment (9%) products are designed to support image-guided minimally invasive treatments in cardiology, interventional radiology, and surgery. North America represents 41% of total sales, Europe, Middle East, and Africa 32%, and Asia-Pacific including China the remainder.